Expand all sections

Olaparib

Lynparza

Extended indication

Treatment in combination with abiraterone acetate in patients with metastatic Castration-resistant P

Therapeutic value

No estimate possible yet
Total cost

195,000,000.00
Registration phase

Clinical trials

Product

Active substance

Olaparib
Domain

Oncology and Hematology
Reason of inclusion

Indication extension
Main indication

Prostate cancer
Extended indication

Treatment in combination with abiraterone acetate in patients with metastatic Castration-resistant Prostate Cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting).
Proprietary name

Lynparza
Manufacturer

AstraZeneca
Mechanism of action

PARP inhibitor
Route of administration

Oral
Therapeutical formulation

Tablet
Budgetting framework

Intermural (MSZ)

Registration

Registration route

Centralised (EMA)
Type of trajectory

Normal trajectory
ATMP

No
Submission date

2021
Expected Registration

2022
Orphan drug

No
Registration phase

Clinical trials
Additional remarks 
Fabrikant verwacht indiening eind 2021 en registratie eind 2022

Therapeutic value

Therapeutic value

No estimate possible yet
Substantiation

Er zijn nog geen resultaten uit de studie bekend. De verwachting is echter dat het mogelijk een grote impact kan hebben in deze lijn.
Frequency of administration

2 times a day
Dosage per administration

300 mg
References 
NCT03732820

Expected patient volume per year

Patient volume

< 3,000

Market share is generally not included unless otherwise stated.
References 
NKR, CAPRI en Zinnige Zorg verbetersignalement: Zinnig gebruik van geneesmiddelen bij patiënten met castratie refractair prostaatcarcinoom
Additional remarks 
Totaal aantal nieuwe prostaatkankerpatiënten per jaar is meer dan 12.000. Patiënten geregistreerd in de NKR 2016 met "cM0cNX, cM0cN0, cMcN1, cM1, pM1" betreft 8.226 in totaal. Het gaat hierbij om zo’n 2.400-3.000 CRPC patiënten (bron: CAPRI). Gezien bijna alle patiënten met CRPC uitzaaiingen hebben is de verwachting bijna de gehele groep mCRPC patiënten betreft.

Expected cost per patient per year

Cost

< 65,000.00
Additional remarks 
Prijs per jaar is (4*€44,46*365)  is zo'n €65.000. Echter, de behandelduur is nog niet bekend.

Potential total cost per year

Total cost

195,000,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension

No
References 
Fabrikant

Other information

There is currently no futher information available.